References
- Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010;116:5555-63
- Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008;6:109-18
- Weycker D, Barron R, Kartashov A, et al. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract 2014;20:190-8
- Weycker D, Li X, Edelsberg J, et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. JOP 2015;11:47-54
- Michels SL, Barron RL, Reynolds MW, et al. Costs associated with febrile neutropenia in the US. Pharmacoeconomics 2012;30:809-23
- Amgen, Inc. Neulasta® (pegfilgrastim) Prescribing Information. Amgen, Inc., 2014. http://pi.amgen.com/united_states/neulasta/neulasta_pi_hcp_english.pdf. Accessed May 7, 2015 Thousand Oaks, CA
- Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009;31:1069-81
- Weycker D, Malin J, Barron R, et al. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol 2012;35:267-74
- Weycker D, Li X, Figueredo J, et al. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer 2015; Published online ahead of print 25 November 2015:1-8
- Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. JCO 2006;24:3187-205
- Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline. JCO 2013;31:794-810
- National Comprehensive Care Network. NCCN clinical practice guidelines in oncology: myeloid growth factors version 1. NCCN. 2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed October 13, 2015 Fort Washington, PA
- Fortner BV, Tauer K, Zhu L, et al. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer 2004;4:22
- Houts AC, Loh GA, Fortner BV, et al. Patient and caregiver time burden associated with anaemia treatment in different patient populations. Support Care Cancer 2006;14:1195-204
- Haithcox S, R Ramnes C, Lee H, et al. The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nurs 2003;2:22
- Tomic K, Long S, Li X, et al. A retrospective study of patients’ out-of-pocket costs for granulocyte colony-stimulating factors. J Oncol Pharm Pract January 2013 :1078155212473001. doi:10.1177/1078155212473001. 2013 Dec;19(4):328-37.
- Houtven CHV, Ramsey SD, Hornbrook MC, et al. economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist 2010;15:883-93
- Lauzier S, Lévesque P, Mondor M, et al. Out-of-Pocket costs in the year after early breast cancer among Canadian women and spouses. JNCI J Natl Cancer Inst 2013;105:280-92
- Payne S, Jarrett N, Jeffs D. The impact of travel on cancer patients’ experiences of treatment: a literature review. Eur J Cancer Care (Engl) 2000;9:197-203
- Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer 1993;72:594-601
- Guidry JJ, Aday LA, Zhang D, et al. Transportation as a barrier to cancer treatment. Cancer Pract 1997;5:361-6
- Athas WF, Adams-Cameron M, Hunt WC, et al. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. JNCI J Natl Cancer Inst 2000;92:269-71
- Meden T, St. John-Larkin C, Hermes D, et al. Relationship between travel distance and utilization of breast cancer treatment in rural northern Michigan. JAMA 2002;287:111
- Rutter CE, Yu JB, Wilson LD, et al. Assessment of national practice for palliative radiation therapy for bone metastases suggests marked underutilization of single-fraction regimens in the United States. Int J Radiat Oncol Biol Phys 2015;91:548-55
- Wu JSY, Kerba M, Wong RKS, et al. Patterns of practice in palliative radiotherapy for painful bone metastases: impact of a regional rapid access clinic on access to care. Int J Radiat Oncol Biol Phys 2010;78:533-8
- Huang LC, Ma Y, Ngo JV, et al. What factors influence minority use of NCI cancer centers? Cancer 2014;120:399-407
- Haddad AQ, Singla N, Gupta N, et al. Association of distance to treatment facility on quality and survival outcomes after radical cystectomy for bladder cancer. Urology 2015;85:876-82
- Lin CC, Bruinooge SS, Kirkwood MK, et al. Association between geographic access to cancer care, insurance, and receipt of chemotherapy: geographic distribution of oncologists and travel distance. JCO August 2015: JCO.2015.61.1558. doi:10.1200/JCO.2015.61.1558. 2015 Oct 1;33(28):3177-85.
- Massarweh NN, Chiang Y-J, Xing Y, et al. Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. J Clin Oncol 2014;32:942-8
- Punglia RS, Weeks JC, Neville BA, et al. Effect of distance to radiation treatment facility on use of radiation therapy after mastectomy in elderly women. Int J Radiat Oncol Biol Phys 2006;66:56-63
- Schroen AT, Brenin DR, Kelly MD, et al. Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients. J Clin Oncol 2005;23:7074-80
- Onega T, Duell EJ, Shi X, et al. Determinants of NCI Cancer Center attendance in medicare patients with lung, breast, colorectal, or prostate cancer. J Gen Intern Med 2009;24:205-10
- Onega T, Cook A, Kirlin B, et al. The influence of travel time on breast cancer characteristics, receipt of primary therapy, and surveillance mammography. Breast Cancer Res Treat 2011;129:269-75
- Peipins LA, Graham S, Young R, et al. Racial disparities in travel time to radiotherapy facilities in the Atlanta metropolitan area. Soc Sci Med 2013;89:32-8
- Li X, Barron R, Tzivelekis S, et al. A prospective study of patterns of chemotherapy, G-CSF use, and burden of G-CSF injections in early-stage breast cancer (ESBC). San Antonio, TX, 2015 Poster presented at the 2015 San Antonio Breast Cancer Symposium 9 December 2015
- AARP Public Policy Institute. Valuing the Invaluable 2015 Update: undeniable progress, but big gaps remain. AARP, 2015. http://www.aarp.org/content/dam/aarp/ppi/2015/valuing-the-invaluable-2015-update-undeniable-progress.pdf. Accessed July 17, 2015 Washington DC
- Tranmer JE, Guerriere DN, Ungar WJ, et al. Valuing patient and caregiver time: a review of the literature. Pharmacoeconomics 2005;23:449-59
- Howlader N, Noone A-M, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2012. Bethesda, MD: National Cancer Institute, 2015. http://seer.cancer.gov/csr/1975_2012/. Accessed May 22, 2015
- American Cancer Society. Cancer treatment & survivorship facts & figures 2014–2015. Atlanta, GA: American Cancer Society, 2015. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042801.pdf. Accessed June 9, 2015
- Chemocare.com. How long is chemotherapy given? - What is chemotherapy? - Chemocare. http://chemocare.com/chemotherapy/what-is-chemotherapy/how-long-is-chemotherapy-given.aspx. Accessed September 8, 2015 Chemocare.com, Cleveland OH, 2015
- Amgen, Inc. Data on File. Amgen, Inc., 2015 Thousand Oaks, CA
- Phillips J, Ritter S, Starner C, et al. Filgrastim (Neupogen) and pegfilgrastim (Neulasta): cost analysis and utilization management opportunity assessment. 2012 https://www.primetherapeutics.com/specialty/assets/pdf/NeupogenNeulastaUMOpportunity.pdf. Accessed May 12, 2015 Poster presented at the AMCP 24th Annual Meeting April 20, 2012 San Francisco CA
- Bureau of Labor Statistics. Occupational Employment Statistics (OES) data as of May 2014. Bureau of Labor Statistics. http://www.bls.gov/oes/current/oes_nat.htm#00-0000. Accessed April 8, 2015 National Conference of State Legislatures, Washington DC. Published 2015 Poster presented at the AMCP 24th Annual Meeting April 20, 2012 San Francisco CA.
- National Conference of State Legislatures. State Minimum Wages | 2015 Minimum Wage by State. http://www.ncsl.org/research/labor-and-employment/state-minimum-wage-chart.aspx#1. Accessed September 14, 2015
- Genworth Financial. Genworth 2014 Cost of Care Survey, April 2014. 2014. https://www.genworth.com/dam/Americas/US/PDFs/Consumer/corporate/130568_032514_CostofCare_FINAL_nonsecure.pdf. Accessed September 3, 2015 Genworth Financial, Richmond VA
- Internal Revenue Service. Standard mileage rates. IRS. 2015. http://www.irs.gov/Tax-Professionals/Standard-Mileage-Rates. Accessed September 8, 2015 Washington DC
- APTA. 2014 Public Transportation Fact Book. Washington, DC: American Public Transportation Association, 2014. http://www.apta.com/resources/statistics/Documents/FactBook/2014-APTA-Fact-Book.pdf. Accessed September 3, 2015
- TaxiFareFinder. Summary taxi rates for US Cities. TaxiFareFinder. http://www.taxifarefinder.com/rates.php. Published 2015. Accessed September 3, 2015
- Centers for Medicare & Medicaid Services. ASP Drug Pricing Files. Centers for Medicare & Medicaid Services. 2015. http://www.cms.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/downloads/2015-April-ASP-Pricing-File.zip. Accessed September 3, 2015 Baltimore MD
- Kaiser Family Foundation. Medicaid benefits: physician services. Kaiser Family Foundation, 2015. http://kff.org/medicaid/state-indicator/physician-services/. Accessed September 11, 2015
- Medicare Payment Advisory Commission (US). Health Care spending and the Medicare Program: a data book June 2015. Washington, DC: Medicare Payment Advisory Commission, 2015. http://www.medpac.gov/documents/data-book/june-2015-databook-health-care-spending-and-the-medicare-program.pdf?sfvrsn=0. Accessed August 27, 2015 Washington DC
- Bureau of Labor Statistics. Consumer Price Index - Urban (CPI-U) Medical Care. Bureau of Labor Statistics Data. http://data.bls.gov/timeseries/CUUR0000SAM?output_view=pct_12mths. Accessed August 31, 2015 Washington DC 2015
- Quach D, Liede A, Byekwaso S, et al. Projection methods using oncology electronic health records to produce nationally representative estimates. 2013. http://obroncology.com/imshealth/content/ISPE%202013_Quach%20poster_13Aug2013.pdf. Accessed May 28, 2015 Poster presented at 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 25-28 2013, Montreal Canada
- DeMartino JK, Larsen JK. Data needs in oncology: “Making sense of the big data soup”. J Natl Compr Canc Netw 2013;11(2 Suppl):S-1-S-12
- Hernandez RK, Quigley J, Pirolli M, et al. Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US. Support Care Cancer 2014;22:2697-705
- Amgen, Inc. SEC Filings. Amgen, Inc. http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-sec. Accessed May 27, 2015 Thousand Oaks CA 2015
- Beveridge RA, Rifkin RM, Moleski RJ, et al. Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacother J Hum Pharmacol Drug Ther 2003;23:101S-109S
- Meehan K, Tchekmedyian, S, Ciesla G. The burden of weekly epoetin alfa injections to patients and their caregivers abstract 2186. J Support Oncol 2003;1(Suppl):28
- Shreay S, Desrosiers M-P, Corey-Lisle P, et al. A retrospective study to evaluate the time burden associated with outpatient red blood transfusions indicated for anemia due to concomitantly administered chemotherapy in cancer patients. Support Care Cancer 2013;21:1335-40
- Meehan K, Tchekmedyian, S, Smith S. An activity-based costing estimate of anemia correction activities in an oncology practice. Abstract 5595. Blood 2002;100:
- Davidoff AJ, Erten M, Shaffer T, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer 2013;119:1257-65
- Finkelstein EA, Tangka FK, Trogdon JG, et al. The personal financial burden of cancer for the working-aged population. Am J Manag Care 2009;15:801-6
- Bestvina CM, Zullig LL, Yousuf Zafar S. The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncol 2014;10:2189-99
- Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84
- Weycker D, Barron R, Edelsberg J, et al. Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res 2014;14:189
- Ramsey SD, McCune JS, Blough DK, et al. Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care 2010;16:678-86
- Rajan SS, Carpenter WR, Stearns SC, et al. Short-term costs associated with primary prophylactic G-CSF use during chemotherapy. Am J Manag Care 2013;19:150-9.
- Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 2007;13:337-48
- Barnes G, Pathak A, Schwartzberg L. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med 2014;3:1477-84.
- Chrischilles EA, Cosler LE, Delgado DJ. Pharmacoeconomics and considerations for injectable products: focus on colony-stimulating factors. JCMP 2003;9:4-21
- Weycker D, Li X, Barron R, Figueredo J, et al. Risk of febrile neutropenia (FN) in cancer patients (pts) receiving myelosuppressive chemotherapy and pegfilgrastim prophylaxis (PEG-P): does day of administration matter? J Clin Oncol 2015;33(Suppl):abstract e17697
- Johnson P. A discrete choice experiment to examine preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors (G-CSF) in previously treated breast cancer patients. J Clin Oncol 2013;31(Suppl):abstract e17509
- Amgen, Inc. Neulasta® Onpro™ Kit. Amgen, Inc. http://www.neulastahcp.com/characteristics/neulasta-onpro-kit/. Accessed December 29, 2015 Thousand Oaks, CA 2015
- Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007;12:478-83